A chimeric epidermal growth factor with fibrin affinity promotes repair of injured keratinocyte sheets.

The aim of the present study is to create a novel chimeric protein of epidermal growth factor (EGF) with fibrin affinity and demonstrate its potential for repairing injured tissues by immobilization to fibrin. The chimeric protein (FBD-EGF) was produced by the fusion of the fibronectin fibrin-binding domain (FBD) to EGF. It showed dose-dependent binding to fibrin and its binding was stable for at least 7days, while native EGF showed little affinity. FBD-EGF promoted the growth of fibroblasts and keratinocytes in the fibrin-bound state as well as in the soluble state. Its activity was further studied in a keratinocyte culture system in which fibrin was exposed upon injury of cell sheets. Fibrin-bound FBD-EGF promoted growth of the sheets over the injured area at a significantly faster rate (approximately eightfold) than native EGF (p<0.01). Wounds 2mm wide were closed in 7-9days. This repair process was inhibited by anti-EGF. Keratinocytes proliferated more extensively in the leading edges of sheets contacting fibrin with FBD-EGF, approximately 1.7-fold more than in the adjacent regions. These results imply that the stable binding of chimeric EGF to fibrin is effective for the repair of injured keratinocyte sheets, suggesting a potential use in tissue engineering.

[1]  D. Leavesley,et al.  Responses of keratinocytes to substrate-bound vitronectin: growth factor complexes. , 2005, Experimental cell research.

[2]  Kenneth M. Yamada,et al.  Fibronectin Domains and Receptors , 1989 .

[3]  S. Andreadis,et al.  A novel role of fibrin in epidermal healing: plasminogen-mediated migration and selective detachment of differentiated keratinocytes. , 2003, The Journal of investigative dermatology.

[4]  J. Hubbell,et al.  Development of growth factor fusion proteins for cell‐triggered drug delivery , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  I. Campbell,et al.  Further characterization of the NH2-terminal fibrin-binding site on fibronectin. , 1994, The Journal of biological chemistry.

[6]  G. Carpenter,et al.  Human epidermal growth factor: isolation and chemical and biological properties. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Cohen,et al.  The stimulation of epidermal proliferation by a specific protein (EGF). , 1965, Developmental biology.

[8]  Yoshihiro Ito,et al.  Covalently immobilized biosignal molecule materials for tissue engineering. , 2007, Soft matter.

[9]  Krishanu Saha,et al.  Multivalency of Sonic hedgehog conjugated to linear polymer chains modulates protein potency. , 2008, Bioconjugate chemistry.

[10]  I. Kato,et al.  Construction and characterization of a fusion protein with epidermal growth factor and the cell‐binding domain of fibronectin , 1992, FEBS letters.

[11]  D. Gospodarowicz,et al.  Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin , 1978, The Journal of cell biology.

[12]  T. Kitajima,et al.  Delivery of a growth factor fusion protein having collagen-binding activity to wound tissues. , 2003, Artificial organs.

[13]  D. Gottlieb,et al.  Optimization of fibrin scaffolds for differentiation of murine embryonic stem cells into neural lineage cells. , 2006, Biomaterials.

[14]  P. Simpson‐Haidaris,et al.  Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. , 2003, Blood.

[15]  Yann Barrandon,et al.  Cell migration is essential for sustained growth of keratinocyte colonies: The roles of transforming growth factor-α and epidermal growth factor , 1987, Cell.

[16]  L Sedel,et al.  A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. , 2003, Biomaterials.

[17]  G. Bradshaw,et al.  Supplementary factors required for serum-free culture of rat kidney cells of line NRK-49F , 1983, In Vitro.

[18]  Jeffrey A. Hubbell,et al.  Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth , 2004, Circulation research.

[19]  J. Hubbell,et al.  Covalently conjugated VEGF--fibrin matrices for endothelialization. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Yoshihiro Ito,et al.  Surface modification of plastic, glass and titanium by photoimmobilization of polyethylene glycol for antibiofouling. , 2007, Acta biomaterialia.

[21]  Zee Upton,et al.  Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor. , 2008, Endocrinology.

[22]  J M Davidson,et al.  Sustained release of epidermal growth factor accelerates wound repair. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Ana D. Lopez,et al.  A novel approach to increase human islet cell mass while preserving beta-cell function. , 2002, Diabetes.

[24]  H. Okochi,et al.  An in vitro outgrowth culture system for normal human keratinocytes. , 2004, Journal of dermatological science.

[25]  O. Matsushita,et al.  Collagen-binding growth factors: production and characterization of functional fusion proteins having a collagen-binding domain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Yoshihiro Ito,et al.  A fusion protein of hepatocyte growth factor for immobilization to collagen. , 2007, Biomaterials.

[27]  H. Green,et al.  Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes , 1977, Nature.

[28]  M. Mosesson.  Fibrinogen and fibrin structure and functions , 2005, Journal of thrombosis and haemostasis : JTH.

[29]  Frank P T Baaijens,et al.  Fibrin as a cell carrier in cardiovascular tissue engineering applications. , 2005, Biomaterials.

[30]  D. Puleo,et al.  The use of N-terminal immobilization of PTH(1-34) on PLGA to enhance bioactivity. , 2008, Biomaterials.

[31]  L. Medved,et al.  The NH2-terminal fibrin-binding site of fibronectin is formed by interacting fourth and fifth finger domains. Studies with recombinant finger fragments expressed in Escherichia coli. , 1994, The Journal of biological chemistry.

[32]  Laura J Suggs,et al.  Three-dimensional culture for expansion and differentiation of mouse embryonic stem cells. , 2006, Biomaterials.

[33]  K. Yamada,et al.  Domain structure of the carboxyl-terminal half of human plasma fibronectin. , 1983, The Journal of biological chemistry.

[34]  T. Kitajima,et al.  Production of a biologically active epidermal growth factor fusion protein with high collagen affinity. , 2001, Journal of biochemistry.

[35]  E. Kobatake,et al.  Construction of epidermal growth factor fusion protein with cell adhesive activity. , 2006, Biomaterials.

[36]  Shinsuke Yuasa,et al.  A new method for manufacturing cardiac cell sheets using fibrin-coated dishes and its electrophysiological studies by optical mapping. , 2005, Artificial organs.

[37]  Franz E Weber,et al.  Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. , 2005, Biotechnology and bioengineering.

[38]  Olena Kravchuk,et al.  Vitronectin: growth factor complexes hold potential as a wound therapy approach. , 2008, The Journal of investigative dermatology.